Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  title={Sipuleucel-T immunotherapy for castration-resistant prostate cancer.},
  author={Philip W. Kantoff and Celestia S. Higano and Neal D. Shore and Elizabeth R. Berger and Eric J. Small and David F Penson and Charles H. Redfern and Anna C. Ferrari and Robert Dreicer and Robert Brownell Sims and Yi Xu and Mark Walter Frohlich and Paul Schellhammer},
  journal={The New England journal of medicine},
  volume={363 5},
BACKGROUND Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. METHODS In this double-blind, placebo-controlled, multicenter phase 3 trial, we randomly assigned 512 patients in a 2:1 ratio to receive either sipuleucel-T (341 patients) or placebo (171 patients) administered intravenously every 2 weeks, for a total of three infusions. The primary end point was… 

Figures and Tables from this paper

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  • C. Nabhan
  • Medicine
    The New England journal of medicine
  • 2010
The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and there was a relative reduction in the risk of death as compared with the placebo group.

Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

  • Medicine, Psychology
  • 2012
The hypothesis that the subgroup of patients who were less than 65 years of age also benefit from treatment with sipuleucel-T is supported, with the trend actually favoring a greater treatment effect in the younger subgroup (Dendreon data on file).

Sipuleucel-T for prostate cancer: the immunotherapy era has commenced

Although no difference in time to progression was observed, a survival advantage was achieved, with a statistically meaningful 4.1-month improvement in median survival in the active arm with respect to the placebo arm.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis

The use of sipuleucel-T prolonged the overall survival among men with mCRPC and the safety profile was acceptable.


Almost all patients treated with sipuleucel-T in clinical trials reported an adverse event, although these were mild or moderate in severity (grade 1 or 2) in most patients.

Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer

The survival benefit, adverse event profile, and short course of treatment (4 weeks) associated with sipuleucel-T therapy make it an appealing treatment option for asymptomatic metastatic castrate resistant prostate cancer patients.

Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

Sipuleucel-T was approved by the US Food and Drug Administration on April 29, 2010, as an immunotherapy for late-stage prostate cancer. To manufacture sipuleucel-T, mononuclear cells harvested from

Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer

Sipuleucel-T immunotherapy treatment at the current price with 96.5% certainty is not cost-effective and the specific group of patients who will benefit more from the treatment should be revealed and treated, or the cost of the vaccine should be lowered significantly to increase its economic value.

Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis.

  • T. BotrelO. Clark R. Reis
  • Medicine
    International braz j urol : official journal of the Brazilian Society of Urology
  • 2012
Sipuleucel-T prolongs overall survival in patients with asymptomatic or minimally symptomatic metastatic metastatic castration-refractory prostate cancer (mCRPC).



Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

It is suggested that sipuleucel-T may provide a survival advantage to asymptomatic HRPC patients in a phase III study and was well tolerated.

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade.

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

  • E. SmallP. Fratesi F. Valone
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
Provenge is a novel immunotherapy agent that is safe and breaks tolerance to the tissue antigen PAP and preliminary evidence for clinical efficacy warrants further exploration.

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

Oral satraplatin delayed progression of disease and pain in patients with metastatic CRPC experiencing progression after initial chemotherapy but did not provide a significant OS benefit.

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

  • P. KantoffT. Schuetz W. Godfrey
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
PROSTVAC-VF immunotherapy was well tolerated and associated with a 44% reduction in the death rate and an 8.5-month improvement in median OS in men with mCRPC, providing preliminary evidence of clinically meaningful benefit but need to be confirmed in a larger phase III study.

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

  • P. KantoffS. Halabi N. Vogelzang
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
M+H generated more frequent responses and a delay in both time to treatment failure and disease progression compared with hydrocortisone alone, and there was an indication that QOL was better with M+H, in particular with respect to pain control.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plusprednisone.